Friday 6 November 2026 Export RVTY’s income statement to Excel — free account

Revvity Inc.

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.

Revenue: +4.29%
EPS: +2.17%
Free cash flow: +27.0%
Total debt: −18.1%

Quarter to September 2026, against a year earlier

150.97 8.46 −5.31%

Follow RVTY

Alert me

Market cap: $16.8B
P/E: 71.9×
Fwd P/E: 66.2×
Dividend yield: 0.19%
F-score: 6/9
Altman Z: 2.49
Beneish M: −2.45
Dividend safety: 80/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Revvity Inc. (RVTY) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Life Sciences	1,431	50.11%
Diagnostics	1,425	49.89%
Gross margin		54.77%
Operating margin		12.49%
Pre-tax margin		9.39%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Product	2,390 83.68%	2,338 84.87%	2,416 87.83%	2,635 79.55%	2,735 71.45%	2,281 85.64%	2,017 69.95%	1,935 69.67%	1,477 65.46%	1,397 66.03%
Service	466 16.32%	417 15.13%	335 12.17%	677 20.45%	1,093 28.55%	382 14.36%	867 30.05%	843 30.33%	780 34.54%	719 33.97%
Revenue	2,856	2,755	2,751	3,312	3,828	2,663	2,884	2,778	2,257	2,116

Gross profit by product or service $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Product	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Service	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Gross profit	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Life Sciences	1,431 50.11%	1,399 50.77%	1,458 53.01%	1,293 39.04%	896 23.40%	596 22.39%	1,746 60.55%	1,693 60.95%	1,578 69.94%	1,513 71.52%	1,528 72.62%	1,484 71.70%	—	—	—	—	—
Diagnostics	1,425 49.89%	1,356 49.23%	1,292 46.99%	2,019 60.96%	2,932 76.60%	2,067 77.61%	1,138 39.45%	1,085 39.05%	679 30.06%	603 28.48%	576 27.38%	586 28.30%	—	—	—	—	—
Human Health	—	—	—	—	—	—	—	—	—	—	—	—	1,326 61.45%	1,165 55.32%	978 50.97%	794 46.64%	732 47.18%
Environmental Health	—	—	—	—	—	—	—	—	—	—	—	—	832 38.55%	941 44.68%	941 49.03%	908 53.36%	819 52.82%
Revenue	2,856	2,755	2,751	3,312	3,828	2,663	2,884	2,778	2,257	2,116	2,105	2,070	2,158	2,105	1,919	1,702	1,551

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Diagnostics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Life Sciences	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Human Health	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Environmental Health	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Americas	1,256 43.98%	1,223 44.39%	1,216 44.19%	1,663 50.20%	1,807 47.20%	1,037 38.94%	1,119 38.80%	—	—	—	—	—	—	—	—	—	—
Europe	825 28.89%	743 26.95%	747 27.16%	832 25.12%	1,217 31.79%	1,022 38.37%	787 27.30%	—	—	—	—	—	—	—	—	—	—
Asia	775 27.14%	789 28.65%	788 28.65%	817 24.68%	804 21.01%	604 22.69%	977 33.90%	—	—	—	—	—	—	—	—	—	—
France	—	—	—	—	—	—	—	98 3.53%	80 3.55%	71 3.36%	71 3.36%	78 3.75%	82 3.79%	84 4.01%	85 4.45%	82 4.84%	77 4.93%
Italy	—	—	—	—	—	—	—	96 3.45%	77 3.43%	71 3.35%	71 3.38%	81 3.91%	78 3.62%	70 3.31%	75 3.91%	67 3.96%	69 4.44%
Indiana	—	—	—	—	—	—	—	92 3.32%	85 3.76%	44 2.07%	40 1.91%	—	—	—	—	—	—
Japan	—	—	—	—	—	—	—	79 2.85%	76 3.38%	66 3.12%	69 3.30%	90 4.36%	96 4.43%	114 5.43%	90 4.69%	76 4.45%	69 4.44%
Korea, Republic Of	—	—	—	—	—	—	—	60 2.16%	—	—	—	—	—	—	—	—	—
Also reported: a second breakdown of the same revenue
UNITED STATES	1,126 39.43%	1,098 39.85%	1,118 40.63%	1,547 46.70%	1,682 43.95%	922 34.60%	974 33.78%	906 32.63%	837 37.09%	842 39.82%	854 40.59%	795 38.39%	827 38.33%	813 38.62%	726 37.83%	667 39.22%	596 38.45%
Other International	1,000 35.02%	932 33.82%	860 31.26%	1,153 34.81%	1,338 34.96%	1,112 41.76%	1,257 43.59%	672 24.18%	569 25.23%	529 24.99%	546 25.96%	600 28.97%	587 27.23%	583 27.70%	563 29.32%	489 28.71%	436 28.12%
CHINA	425 14.88%	450 16.33%	454 16.52%	476 14.38%	450 11.75%	306 11.48%	582 20.17%	560 20.15%	375 16.61%	337 15.92%	297 14.11%	258 12.45%	255 11.81%	216 10.28%	164 8.55%	132 7.73%	104 6.73%
GERMANY	178 6.22%	163 5.90%	193 7.02%	—	—	—	—	142 5.13%	92 4.06%	90 4.25%	87 4.12%	88 4.25%	99 4.60%	106 5.02%	113 5.91%	92 5.39%	95 6.15%
UNITED KINGDOM	127 4.44%	113 4.10%	125 4.56%	136 4.11%	358 9.35%	324 12.16%	71 2.45%	72 2.60%	65 2.89%	66 3.12%	69 3.28%	81 3.92%	134 6.19%	119 5.63%	102 5.34%	97 5.71%	104 6.73%
Total international	1,730	1,657	1,633	1,765	2,146	1,742	1,909	1,872	1,420	1,273	1,250	1,275	1,331	1,292	1,193	1,034	954
Revenue	2,856	2,755	2,751	3,312	3,828	2,663	2,884	2,778	2,257	2,116	2,105	2,070	2,158	2,105	1,919	1,702	1,551

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.